Volume: 52 Issue: 3
Year: 2021, Page: 211-221, Doi: https://doi.org/10.51966/jvas.2021.52.3.211-221
Received: Aug. 12, 2021 Accepted: Aug. 22, 2021 Published: Sept. 30, 2021
Rabies continues to be one of the most deadly infectious diseases known to human race since antiquity, with a case fatality rate almost 100 per cent after the onset of clinical disease. The disease still has a significant impact on human and animal living all over the globe. It is found on all continents where terrestrial animals exist, with the bulk of animal and human cases documented in resource-constrained African and Asian countries, where thousands of human deaths are being recorded annually. The disease produces one of the most agonising deaths in humans and it is likely that the global statistic of roughly 59,000 human rabies fatalities per year is an underestimate. Scientific innovations that led to the successful development of several vaccines and immunisation policies in identified ‘at risk’human and animal populationshave gained a great reputation in minimising the impact of disease across wide portions of the globe.Vaccines continue to be the most significant triumphs of the combined global efforts of the public and animal health communities and has achieved significant strides in the treatment, prevention, and control of disease. This paper describes the history, evolution, and accomplishments of human ingenuity, scientific endeavour, and the joint global efforts of the public and animal health communities that resulted in evolving an effective prevention and control strategies.
Keywords: Evolution, history, rabies, vaccination
Astray, R. M., Ventini, D. C., Boldorini, V. L. L., Silva, F. G., Rocca, M. P. and Pereira, C. A. 2014. Rabies virus glycoprotein and immune response pattern using recombinant protein or recombinant RNA viral vectors. Vaccine. 32:2829–32.
Baer, G. M. 2007. The history of rabies. In Rabies. Academic Press. 86p.
Barrett, P. N., Mundt, W., Kistner, O. and Howard, M. K. 2009. Vero cell platform in vaccine production: Moving towards cell culture-based viral vaccines. Expert Rev Vaccines. 8 :607–618.
Barth, R., Meslin, F. X., Kaplan, M. M., Koprowski, H. and Franke, V.1996. Laboratory techniques in rabies. (4th Ed.). WHO, Geneva, 350p.
Barth, R., Gruschkau, H., Jaeger, O., Milcke, L. and Weinmann E. 1984. Purified chick embryo cell (PCEC) rabies vaccine for human use. Laboratory data. Behring Inst Mitt. 76:142–154.
Briggs, D. J., Dreesen, D. W., Nicolay, U., Chin, J. E., Davis, R., Gordon, C. and Banzhoff, A. 2000. Purified chick embryo cell culture rabies vaccine: interchangeability with human diploid cell culture rabies vaccine and comparison of one versus two-dose post-exposure booster regimen for previously immunized persons. Vaccine. 19: 1055-1060.
Carter, K. C. 1982. Nineteenth-century treatments for rabies as reported in the Lancet. Med. Hist. 26: 67-78.
Chen, Z., Zhou, M., Gao, X., Zhang, G., Ren, G., Gnanadurai, C. W., Fu, Z. F. and He, B. 2013. A novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein. J. Virol. 87:2986–2993.
Fuenzalida, E., Palacios, R. and Borgono, J. M. 1964. Antirabies antibody response in man to vaccine made from infected suckling—mouse brains. Bull. World Health Organ. 30:431–436.
Ge, J., Wang, X., Tao, L., Wen, Z., Feng, N., Yang, S., Xia, X., Yang, C., Chen, H. and Bu, Z. 2011. Newcastle disease virusvectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J. Virol. 85:8241–52.
Gongal, G. and Sampath, G. 2019. Introduction of intradermal rabies vaccination–A paradigm shift in improving postexposure prophylaxis in Asia. Vaccine. 37: A94-A98.
Hampson, K., Coudeville, L., Lembo, T., Sambo, M., Kieffer, A., Attlan, M., Barrat, J., Blanton, J. D., Briggs, D. J., Cleaveland, S. and Costa, P. 2015. Estimating the global burden of endemic canine rabies. PLOS Negl. Trop. Dis. 9: p.e0003709.
Hayflick, L. 1989. History of cell substrates used for human biologicals. Dev Biol Stand. 70:11–26.
Hernandez, R., Sinodis, C. and Brown, D. T. 2010. Growth and maintenance of chick embryo fibroblast (CEF). Curr. Protoc. Microbiol. 17: 1–8.
Jordan, I. and Sandig, V. 2014. Matrix and backstage: cellular substrates for viral vaccines. Viruses.6:1672–1700.
Montomoli, E., Khadang, B., Piccirella, S., Trombetta, C., Mennitto, E., Manini, I., Stanzani, V. and Lapini, G. 2012. Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production. Expert Rev. Vaccines. 11: 587-594.
Morimoto, K., Shoji, Y. and Inoue, S. 2005. Characterization of P gene-deficient rabies virus: propagation, pathogenicity and antigenicity. Virus Res. 111:61–67.
Nagarajan, E. and Rupprecht, C. E. 2020. History of rabies and rabies vaccines. In: Hildegund C. J. (ed.). Rabies and Rabies vaccines. Springer. Philadelphia, pp: 11- 44.
Niederhauser, S., Bruegger, D., Zahno, M. L., Vogt, H. R., Peterhans, E. and Zanoni, R 2008. A synthetic peptide encompassing the G5 antigenic region of the rabies virus induces high avidity but poorly neutralizing antibody in immunized animals. Vaccine.26: 6749–6753
Pearce, J. M. 2002. Louis Pasteur and rabies: a brief note. J. Neurol. Neurosurg. Psychiatry. 73: 82-88.
Peck, F. B. Jr., Powell, H. M. and Culbertson, C. G. 1955. A new antirabies vaccine for human use; clinical and laboratory results using rabies vaccine made form embryonated duck eggs. J. Lab. Clin. Med. 45:679–783.
Ramya, R., MohanaSubramanian, B., Sivakumar, V., Senthilkumar, R. L., Sambasiva Rao, K. R. S. and Srinivasan, V. A. 2011. Expression and solubilization of insect cell-based rabies virus glycoprotein and assessment of its immunogenicity and protective efficacy in mice. Clin. Vaccine Immunol.18:1673–9.
Rosner, F. 1974. Rabies in the Talmud. Med. Hist. 18: 198-200.
Rupprecht, C. E., Hanlon, C. A. and Hemachudha, T. 2002. Rabies reexamined. Lancet Infect. Dis. 2:327–343.
Smith, T. G., Wu, X., Franka, R. and Rupprecht, C. E. 2011. Design of future rabies biologics and antiviral drugs. Adv.Virus Res. 79: 345–363.
Wang, X., Bao, M., Wan, M., Wei, H., Wang, L. and Yu, H. 2008. A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine. 26: 1893–1901.
Warrell, M. J., Nicholson, K. G., Chanthavanich, P., Sinhaseni, A., Xueref, C., Suntharasamai, P., Warrell, D. A., Viravan, C., Phanfung, R. and Vincent-Falquet, J. C. 1984. Multi-site intradermal and multisite subcutaneous rabies vaccination: improved economical regimens. Lancet. 323: 874-876.
WHO (World Health Organization). 2018a. Rabies vaccines and immunoglobulins: WHO position. WHO/CDS/NTD/ NZD/2018.04.
WHO. (World Health Organization). WHO expert consultation on rabies. 2018b. Third report TRS1012. Geneva, Switzerland.
Wiktor, T. J., Fernandes, M. V. and Koprowski, H. 1964. Cultivation of rabies virus in human diploid cell strain WI-38. J. Immunol. 93:353–66.
Wilkinson, L. 1977. The development of the virus concept as reflected in corpora of studies on individual pathogens. RabiesTwo millennia of ideas and conjecture on the aetiology of a virus disease. Med. Hist. 21: 15-31.
Wu, Q., Yu, F., Xu, J., Li, Y., Chen, H., Xiao, S., Fu, Z. F. and Fang, L. 2014. Rabies-virusglycoprotein pseudotyped recombinant baculovirus vaccine confers complete protection against lethal rabies virus challenge in a mouse model. Vet Microbiol. 171:93–101.
© 2021 Vijayakumar and Jose. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Vijayakumar, K. and Jose, K.R. 2021. History, evolution and newer perspectives of rabies vaccines. J. Vet. Anim. Sci. 52(3): 211-221.
DOI: https://doi.org/10.51966/jvas.2021.52.3.211-221